Cooley Advised Ambros Therapeutics on $550 Million Merger With Werewolf Therapeutics, Concurrent $150 Million Private Financing
Cooley advised Ambros Therapeutics, a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with high unmet medical need, on its definitive merger agreement with Werewolf Therapeutics for approximately $550 million. Upon completion of the merger, the combined company will operate as Ambros Therapeutics, headquartered in San Diego, California, and is expected to trade under the Nasdaq ticker symbol “AMBX”.
In connection with the transaction, Cooley also advised Ambros Therapeutics on a concurrent private financing of $150 million from a syndicate of leading healthcare-dedicated investors co-led by RA Capital Management and Janus Henderson Investors.
The transaction was announced publicly in this press release.
William Sorabella, Rita Sobral, Jason Kent, Sydney Sawyier, Kristin VanderPas, Peter Haddad, Joe Sandys, and Arda Tekin led the Cooley team advising Ambros Therapeutics.
Cooley previously advised Ambros Therapeutics on its $125 million Series A financing in 2025.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.